Compare PCB & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PCB | ZURA |
|---|---|---|
| Founded | 2003 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 325.6M | 252.9M |
| IPO Year | N/A | N/A |
| Metric | PCB | ZURA |
|---|---|---|
| Price | $22.46 | $4.50 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $24.50 | $11.38 |
| AVG Volume (30 Days) | 26.5K | ★ 439.9K |
| Earning Date | 01-29-2026 | 11-13-2025 |
| Dividend Yield | ★ 3.57% | N/A |
| EPS Growth | ★ 43.50 | N/A |
| EPS | ★ 2.41 | N/A |
| Revenue | ★ $107,743,000.00 | N/A |
| Revenue This Year | $21.55 | N/A |
| Revenue Next Year | $8.65 | N/A |
| P/E Ratio | $9.30 | ★ N/A |
| Revenue Growth | ★ 13.61 | N/A |
| 52 Week Low | $16.00 | $0.97 |
| 52 Week High | $24.04 | $4.68 |
| Indicator | PCB | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | 50.16 | 68.03 |
| Support Level | $23.03 | $4.00 |
| Resistance Level | $24.04 | $4.44 |
| Average True Range (ATR) | 0.63 | 0.25 |
| MACD | -0.09 | 0.05 |
| Stochastic Oscillator | 45.33 | 92.46 |
PCB Bancorp is a bank holding company, which engages in the provision of consumer and commercial banking services. It provides Personal, Business, and Loan services, which provide banking, lending, and digital, tools, home loans, and others. Also, it offers a broad range of loans, deposits, and other products and services predominantly to small and middle-market businesses and individuals. The company provided it's services in Los Angeles and Orange Counties, California; Bellevue, Washington; and Atlanta, Georgia.
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.